SCHEMBL13778140

SCHEMBL13778140

Cc1ccc(NC(=O)c2ccnc3[nH]c(-c4ccc(F)cc4)nc23)c(C)n1

nearest known ligand 0.55

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 14/20 0.55
GSK3A P49840 1/20 0.43
NTRK1 P04629 1/20 0.42
NTRK2 Q16620 1/20 0.42
GPR6 P46095 1/20 0.37
PTK2 Q05397 1/20 0.37
LMNA P02545 1/20 0.37
ESR1 P03372 1/20 0.37
PARP1 P09874 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152286 0.88 GSK3B (0.54) GSK3BGSK3APARP1
SCHEMBL4152791 0.84 GSK3B (0.73) GSK3BPARP1
SCHEMBL4152959 0.84 GSK3B (0.49) GSK3BGSK3APTK2LMNAESR1
SCHEMBL4145763 0.84 GSK3B (0.53) GSK3BGSK3ALMNAESR1
SCHEMBL4161701 0.83 GSK3B (0.59) GSK3BGSK3ALMNAESR1
SCHEMBL8237367 0.81 GSK3B (0.49) GSK3BGSK3ALMNAESR1PARP1
SCHEMBL4169257 0.80 GSK3B (0.49) GSK3BGSK3ALMNAESR1PARP1
SCHEMBL4166762 0.80 GSK3B (0.48) GSK3BGSK3A
SCHEMBL4153157 0.80 GSK3B (0.48) GSK3BGSK3ANTRK1LMNAESR1
SCHEMBL4154229 0.79 GSK3B (0.51) GSK3BGSK3APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885GSK3A 2/4885NTRK1 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.